Allogeneic stem cell transplantation (SCT) can cure several nonmalignant diseases in children. However, patients frequently have significant morbidity before transplantation and there is a high transplant-related mortality. Nonmyeloablative SCT might achieve the same goals but with less toxicity. Six pediatric patients with nonmalignant diseases underwent nonmyeloablative SCT from different stem cell sources. All patients were conditioned with fludarabine/melphalan with additional anti-thymocyte globulin for haploidentical grafts and prophylaxis for graft-versus-host disease (GVHD) consisting of tacrolimus and methotrexate with additional prednisolone for haploidentical grafts. Hematopoietic stem cells were neither T-cell depleted nor purged. All patients had severe organ dysfunction that precluded transplantation with conventional conditioning. Five of the six are alive and in complete disease resolution at a median of 19 months (range, 7-53 months) after SCT. One patient died of bacteremia before engraftment. Three patients achieved complete donor chimerism. Two patients remained stable mixed chimerism. Short-term toxicities were minimal. Acute and chronic GVHD were not seen. In summary, the fludarabine-based nonmyeloablative regimen followed by SCT provides a good approach for children with nonmalignant diseases. Even patients with severe organ dysfunctions had adequate engraftment with acceptable toxicities.
Introduction
Allogeneic stem cell transplantation (SCT) has been proven as an effective means of treating various malignant and nonmalignant diseases. 1, 2 The optimal approach to SCT in children with nonmalignant disease who have infection and organ dysfunction has yet to be determined. The beneficial effect of myeloablative regimens, however, is counterbalanced by increased short-and long-term toxicity. In particular, infection and organ dysfunction contribute to the high treatment-related mortality rates seen with conventionally conditioned SCT in older children who have acquired organ dysfunction. 3, 4 Recently, some groups [5] [6] [7] have reported SCT for children with hematological malignancies and nonmalignancies who were on highly immunosuppressive but nonmyeloablative regimens. Such regimens are of interest for children with nonmalignant diseases, as there is no obvious need for intensive therapy or graft-versus-host disease (GVHD). In view of the experimental nature of such an approach, our initial studies were performed on patients in whom SCT with conventional conditioning therapy was contraindicated because of severe complications. We undertook a pilot study to determine engraftment rate, toxicity and GVHD associated with a fludarabine-based regimen 8 and tacrolimus-based GVHD prophylaxis [9] [10] [11] for children with nonmalignant diseases.
Patients and methods

Patients
Six consecutive patients with nonmalignant diseases at Fukushima Medical University underwent SCT (seven SCTs including one second SCT), all of whom were given a fludarabine-based nonmyeloablative conditioning regimen between April 2001 and October 2005. Patients' characteristics, including pre-SCT risk factors, are shown in Table 1 . All of these patients would have been ineligible for a conventional myeloablative SCT, including two with severe combined immunodeficiency (SCID), two with severe chronic active Epstein-Barr virus infection in the active phase, one with chronic granulomatous disease (CGD) and one with hyper-IgM syndrome. The median age at transplantation was 5.2 years (range, 0.5-16.4 years). The HLA typing was confirmed by high-resolution typing in all cases except for unrelated cord blood (UCB), and UCB was confirmed by low-resolution typing. Hematopoietic stem cells were neither T-cell depleted nor purged. Approval was obtained from the Institutional Review Board of the Fukushima Medical University. Informed consent was obtained from patients or guardians before enrollment in a nonmyeloablative SCT protocol. . When patients were able to tolerate oral intake, they were switched to oral tacrolimus at 0.3 mg/kg/day, with the dose divided into two and given every 12 h. The dose was adjusted to maintain trough levels of 7-15 ng/ml during 12 months after SCT and was tapered. Patients receiving non-T-cell-depleted haploidentical transplantations received 2 mg/kg prednisolone per day starting on day 0 together with tacrolimus and methotrexate. Prednisolone was tapered on day 14 in the absence of GVHD. The severity of GVHD was graded according to the consensus criteria. 12 
Conditioning regimen and transplantation
Supportive care
All patients received prophylaxis with trimethoprimsulfamethoxazole against Pneumocystis carinii infection. They received broad-spectrum antibiotics, fluconazole and acyclovir for the prophylaxis of bacterial, fungal and herpesvirus infection, respectively. Additionally, one patient with SCID and disseminated Bacillus CalmetteGuerin (BCG) received antituberculosis therapy with rifampicin and isoniazid. Immunoglobulin (0.2 g/kg/dose, i.v.) was infused weekly until day 100, and then biweekly until 6 months after SCT. G-CSF (5 mg/kg/day) was started on day 1 following the infusion of stem cells. Cytomegalovirus (CMV) treatment with ganciclovir was started when CMV antigenemia was detected on routine weekly examination.
Analysis of chimerism
Chimerism was assessed by standard cytogenetic analysis in male/female donor-recipient combination and the various numbers of tandem repeats analysis with multiple informative alleles in sex-matched donor-recipient combinations.
Results
Toxicity and survival
Five of the six patients are alive and in complete disease resolution (CR) at a median of 19 months (range, 7-53 months). One patient (UPN5) had Pseudomonas aeruginosa bacteremia and disseminated BCG before transplantation and died on day 28 secondary to multi-organ failure. Of the five surviving patients, one patient (UPN4-2) had CMV and human herpesvirus 6 reactivation. One patient (UPN3) developed bacteremia and had CMV and varicella zoster virus reactivation. Three patients in total suffered from bacteremia. Lung bleeding in one and mild mucositis in one were observed and controlled. Veno-occlusive disease and Epstein-Barr virus reactivation were not seen.
Engraftment and chimerism
Primary engraftment occurred in five of the six patients. The median times to neutrophil (4500/ml) and platelet (42 Â 10 4 /ml) recovery were 15 days (range, 11-15 days) and 17 days (range, 14-24 days), respectively. Two patients achieved full donor chimerism on days 20 and 53. Two 
GVHD
Acute and chronic GVHD were not observed even in the second SCT (Table 2 ).
Immune reconstitution
Immune reconstitution was assessed by recovery of CD3 þ , CD4 þ and CD8 þ T cells, phytohemagglutinin A (PHA) stimulation index, and CD19
þ B cells at a median of 19 months (range, 7-53 months) after SCT. All five evaluable patients have had good recovery of T-cell numbers, and have achieved normal age-adjusted CD3 counts. In all patients, CD8 recovery preceded CD4 recovery. Two of the five patients now have normal CD4 counts, and the remaining three patients still have low CD4 counts. With regard to T-cell function, all five patients have had normal PHA stimulation index at 6 months after SCT. In the current study, four of the five patients achieved normal CD19 counts, but none of the patients continued to undergo prophylactic i.v. immunoglobulin replacement therapy.
Quality of life
At the time of writing this report, five of the six patients are alive and well, and have Lansky scores of 90-100% at a median of 19 months after SCT.
Discussion
We have shown that reliable donor stem cell engraftment is possible by using nonmyeloablative conditioning for the patients with severe organ dysfunctions who could not be candidates for SCT with conventional conditioning. Most patients were cured and there was improvement with respect to their severe infections and organ dysfunctions. Although too small for statistical analysis, the overall survival data compare favorably with historical data, 13 particularly for the patients receiving HLA-mismatched transplantations. In our study, two patients receiving cells from an HLA-mismatched donor survive and are in CR. Viral reactivations were frequent, as previously reported for immunosuppressive conditioning, 14 but only one patient died of direct infectious causes.
Engraftment was one of the main end points of this study. Although the patient with SCID did not achieve primary engraftment, he had disseminated BCG infection and Gram-negative bacteremia at the time of transplantation, which was done as a heroic measure. The patient with CGD achieved primary engraftment but subsequently showed late graft failure. In this patient, late graft failure NST for nonmalignant diseases in children A Kikuta et al occurred after the first non-T-cell-depleted HLA haploidentical SCT, despite the sufficient number of infused TNC. The possible risk factors for graft failure in our case seemed to be donor-recipient HLA mismatch, and the first conditioning regimen (fludarabine/melphalan/ATG) may have been insufficient to achieve stable engraftment. 6 The second conditioning including 2-Gy TBI might account for the high rates of engraftment. [15] [16] [17] Although most groups 7,18 using nonmyeloablative conditioning for SCT have reported an incidence of acute GVHD comparable to that seen with conventional SCT, we did not observe acute GVHD. This likely reflects, at least in patients, the younger age of our patients, but it may also be related to our use of tacrolimus. Furthermore, the use of ATG in our regimen for non-T-cell-depleted haploidentical BMT from his mother, so close to the time of stem cell infusion, might have effectively induced partial T-cell depletion in vivo. 19, 20 It is difficult to comment on the frequency of chronic GVHD, but the fact that this complication did not occur is encouraging. Tacrolimus-based prophylaxis regimens are of interest for nonmalignant diseases as there is no obvious need for GVHD.
Finally, we have demonstrated that nonmyeloablative SCT permits rapid engraftment from family and unrelated, matched and mismatched donors with minimal toxicity, even in the presence of severe organ dysfunctions. Clearly, one of the difficulties in drawing conclusion is that we describe heterogeneous diseases with different stem cell sources used. Moreover, the follow-up period is short. Because we avoided conventional-dose TBI and high-dose chemotherapy, we expect that long-term side effects of myeloablative SCT, such as growth retardation and learning disabilities, will be absent in the future of the children of this investigation.
